23andMe Admits ‘Mining’ Your DNA Data Is Its Last Hope
By Thomas Germain,
Gizmodo
| 02. 13. 2024
With the business in a tailspin, 23andMe’s CEO assures investors there’s still plenty of money it can make on your genes.
23andMe is in a death spiral. Almost everyone who wants a DNA test already bought one, a nightmare data breach ruined the company’s reputation, and 23andMe’s stock is so close to worthless it might get kicked off the Nasdaq. CEO Anne Wojcicki is on a crisis tour, promising investors the company isn’t going out of business because she has a new plan: 23andMe is going to double down on mining your DNA data and selling it to pharmaceutical companies.
“We now have the ability to mine the dataset for ourselves, as well as to partner with other groups,” Wojcicki said in an interview with Wired. “It’s a real resource that we could apply to a number of different organizations for their own drug discovery.”
That’s been part of the plan since day one, but now it looks like it’s going to happen on a much larger scale. 23andMe has always coerced its customers into giving the company...
Related Articles
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Jonathan D. Grinstein, Genetic Engineering & Biotechnology News | 06.26.2024
Partial screenshot from The Bridge Recombination Mechanism
video by The Arc Institute on YouTube (CC)
Buried in a family of mobile genetic elements, Arc Institute researchers led by Patrick Hsu, PhD, have discovered an RNA-guided system that enables modular...